Toronto Innovation Acceleration Partners („TIAP“) announced today the launch of a new project developed under the BRIDGE LAB150, a partnership between Evotec SE and TIAP. The project will be focusing on breakthroughs in novel cellular drug screening systems in oncology-focused scientific KRAS research by Professor Igor Stagljar at the University of Toronto, a TIAP Member, and aims to develop therapeutics targeting the protein-protein interactions of KRAS and its downstream interacting partners. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/toronto-innovation-acceleration-partners-tiap-adds-novel-kras-oncology-project-to-its-lab150-portfolio-5879
Working together in the fight against tuberculosis and malaria
New medicines for treating tuberculosis, malaria and other infectious diseases are still urgently needed, particularly in developing countries. The spread of antibiotic-resistant germs also results in a critical shortage of effective medications for treating and containing infectious diseases. Although this is a global problem, developing and emerging countries are particularly affected. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/working-together-in-the-fight-against-tuberculosis-and-malaria-5877
Evotec expands strategic partnership with Celmatix in women's health
Evotec SE today announced an expansion of the Company’s strategic partnership with Celmatix Inc., the leading precision health company advancing the fields of reproductive medicine and fertility at the intersection of big data and genomics. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-strategic-partnership-with-celmatix-in-womens-health-5875
Addressing Discovery and Development Challenges in Biologics
The biologics industry is growing at an incredible rate. While its global market value was estimated at $ 236 bn in 2017, it is expected to rise to $ 310 bn by 2023. As key market players enter the field, competition is increasing. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/addressing-discovery-and-development-challenges-in-biologics-5873
Immunitas Therapeutics Launches with $39 Million Series A to Advance Lead Programs to Human Efficacy Studies Based on a Unique Human Immunology-Focused Drug Development Platform
Immunitas Therapeutics, a single cell genomics-based drug discovery company founded by Longwood Fund, today announced a $39 million Series A financing led by Leaps by Bayer and Novartis Venture Fund and joined by additional investors including Evotec, M Ventures, Alexandria Venture Investments, and other institutional investors. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/immunitas-therapeutics-launches-with-39-million-series-a-to-advance-lead-programs-to-human-efficacy-studies-based-on-a-unique-human-immunology-focused-drug-development-platform-5872
Evotec SE reports first nine-month 2019 results and corporate updates
Evotec SE today reported financial results and corporate updates for the first nine months ended 30 September 2019. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-reports-first-nine-month-2019-results-and-corporate-updates-5864
Merck licenses CRISPR gene-editing technology to Evotec
Merck today announced that it has signed a license agreement providing Evotec SE access to Merck’s foundational CRISPR intellectual property. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/merck-licenses-crispr-gene-editing-technology-to-evotec-5868
Evotec and Vifor Pharma form joint venture for early development in nephrology
Evotec SE and Vifor Pharma today announced the launch of a 50:50 joint venture focused on the discovery and development of novel nephrology therapeutics. Vifor Pharma will be benefiting from access to an external R&D capability for the development of its own nephrology pipeline, while Evotec will gain access to a commercial partner through outlicensing all nephrology assets developed through the joint venture to the Vifor Pharma Group. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-vifor-pharma-form-joint-venture-for-early-development-in-nephrology-5862
Evotec SE to announce results for the first nine months 2019 on 12 November 2019
Evotec SE will announce its financial results for the first nine months of 2019 on Tuesday, 12 November 2019. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-to-announce-results-for-the-first-nine-months-2019–on-12-november-2019-5860
Evotec, Integra Holdings and Yissum establish LAB555 to fast track early-stage drug development
Evotec SE today announced the inauguration of LAB555, an academic BRIDGE partnership with Integra Holdings and Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-integra-holdings-and-yissum-establish-lab555-to-fast-track-early-stage-drug-development-5858